The Latin America, Middle East and Africa Veterinary Pain Management Market would witness market growth of 8.1% CAGR during the forecast period (2023-2030).
A developing major issue in animal healthcare is the prevalence of chronic and other inflammatory illnesses. Osteoarthritis, joint discomfort, and pain from cancers like osteosarcoma are common types of pain that animals experience. Animals with many chronic conditions frequently require surgical treatments, which are painful afterward. This element is also anticipated to generate substantial demand for pain relief products. Additionally, it is projected that the market under examination will profit from the government’s and other organizations’ expanding activities.
A growing number of vaccine development innovations are attracting attention, including mRNA vaccines, the precision system for vaccine delivery, heat-resistant vaccines, and customizable vaccinations. Artificial intelligence, microfluidics, molecular diagnostics, and other user-friendly diagnostic innovation techniques can potentially change the animal health sector. There is an increase in insurance products that primarily cover cases of death from disease or accidents, which includes natural disasters and fatal injuries of other animals. The landscape of animal health is rapidly evolving due to improvements in digital monitoring and surveillance, which increase efficiency and speed. Smart building designs and products like smart tags, sensors, remote monitoring surveillance, and smart tags are becoming more prevalent using digital technology.
Animal diseases are a recurring concern to domestic animals and livestock, and they provide a serious economic barrier to their expansion in Sub-Saharan African nations. Africa is responsible for most livestock diseases recognized by the World Organization for Animal Health (OIE or WOAH), which makes frequent medication administration for animals sufficient. Due to increasing global demand, the cattle industry has recently experienced an explosion. The need for animal care in the region has risen significantly. Additionally, this is anticipated to boost the expansion of the LAMEA region’s market.
The Brazil market dominated the LAMEA Veterinary Pain Management Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $44.5 million by 2030. The Argentina market is anticipated to grow at a CAGR of 8.7% during (2023 - 2030). Additionally, The UAE market would exhibit a CAGR of 7.9% during (2023 - 2030).
Based on Animal type, the market is segmented into Livestock Animal and Companion Animal. Based on End-Use, the market is segmented into Hospitals & Clinics and Others. Based on Indication, the market is segmented into Osteoarthritis, Post-operative pain, and Others. Based on Product, the market is segmented into NSAIDs, Opioids, Anesthetics and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Sant? Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
Scope of the Study
Market Segments covered in the Report:
By Animal type

  • Livestock Animal
  • Companion Animal


By End-Use

  • Hospitals & Clinics
  • Others


By Indication

  • Osteoarthritis
  • Post-operative pain
  • Others


By Product

  • NSAIDs
  • Opioids
  • Anesthetics
  • Others


By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA


Companies Profiled

  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Zoetis, Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health, Inc.
  • Zomedica Corp. (Assisi Animal Health)
  • Norbrook Laboratories Limited
  • Ceva Sant? Animale
  • Dechra Pharmaceuticals PLC
  • Vetoquinol SA (Soparfin SCA)


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free